“I believe immunotherapy has a role in earlier lines of CRC,” he said. “In other diseases, immunotherapy started out in advanced third-line refractory settings and moved into the frontline setting, often in combination with chemotherapy. I hope that’s where we’re heading in CRC. There’s a lot of promise in that.” Read more . . .
Whether its immunotherapy in colorectal cancer (CRC) or chemotherapy in pancreatic cancer, a common thread among these gastrointestinal (GI) malignancies has been the investigation of these agents in earlier settings, explained Douglas A. Nelson, MD.